D. Malone

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
D. Malone, Daniel C Malone, Daniel Malone, D Malone, D. C. Malone, D C Malone, Daniel C. Malone, Dan Malone, Daniel Charles Malone, Dan C Malone
Publication record
341 papers · 10,170 citations · H-index 48

PAPERS

Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)
202317 citationsauthor #7
Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
20236 citationsauthor #7
A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections
202316 citationsauthor #1
Reply: Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)
20231 citationsauthor #1
A machine learning evaluation of patient characteristics associated with prescribing of guideline-directed medical therapy for heart failure
20235 citationsauthor #5
Different vaccination strategies for preventing coronavirus disease 2019 in Kenya: A dynamic modelling study of health impact and cost-effectiveness
20230 citationsauthor #11
Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review
20236 citationsauthor #2
Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective.
202322 citationsauthor #6
Short-term efficacy of non-pharmacological interventions for global population with elevated blood pressure: A network meta-analysis
202312 citationsauthor #8
Age priority in continuous coronavirus disease 2019 booster doses under China's new policy of free-will nucleic acid test: A dynamic model-based effectiveness and cost-effectiveness analysis
20230 citationsauthor #11
Clinician challenges to evidence-based prescribing for heart failure and reduced ejection fraction: A qualitative evaluation.
20238 citationsauthor #3
126-LB: Effect of a Digital Diabetes Solution on All-Cause Health Care Resource Utilization Charges for Patients with Type 2 Diabetes—A Retrospective Cohort Study
20231 citationsauthor #2
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal
20237 citationsauthor #6
Assessing the impact of single or short-term administration on a therapy’s cost-effectiveness: a hypothetical disease-agnostic model
20231 citationsauthor #4
Shared Decision-Making for Drug-Drug Interactions: Formative Evaluation of an Anticoagulant Drug Interaction
20221 citationsauthor #11
Clinician Satisfaction With Advanced Clinical Decision Support to Reduce the Risk of Torsades de Pointes
20221 citationsauthor #7
Evaluation of Shared Decision-Making for Concomitant Warfarin and NSAID Medications using the DDInteract App
20220 citationsauthor #8
Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes
20222 citationsauthor #8
Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
20229 citationsauthor #11
Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management
202234 citationsauthor #10
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
20228 citationsauthor #2
Colchicine and macrolides: a cohort study of the risk of adverse outcomes associated with concomitant exposure
20227 citationsauthor #4
Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S.
20223 citationsauthor #3
Guidelines for composing and assessing a paper on the treatment of pain: A practical application of evidence-based medicine principles to a cost-effectiveness analysis of the MINT randomized clinical trials
20221 citationsauthor #2
Coordinated use of Health Level 7 standards to support clinical decision support: Case study with shared decision making and drug-drug interactions
20228 citationsauthor #3
Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia
20228 citationsauthor #8
Authors’ Response to Yoshihiro Noguchi’s Comment on: “A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)”
20221 citationsauthor #1
The potential for leveraging machine learning to filter medication alerts
202211 citationsauthor #5
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
20229 citationsauthor #8
Risk of Bleeding Among Individuals on Direct-Acting Oral Anticoagulants: An Academic Medical Center Cohort Study
20222 citationsauthor #5
A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)
202213 citationsauthor #6
Changes in Predicted Opioid Overdose Risk Over Time in A State Medicaid Program: A Group-Based Trajectory Modeling Analysis.
20224 citationsauthor #8
Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States
20225 citationsauthor #5
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study.
202233 citationsauthor #6
QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data
20227 citationsauthor #9
Interpretable Machine Learning Prediction of Drug-Induced QT Prolongation: Electronic Health Record Analysis
202215 citationsauthor #3
Relationship between a risk score for QT interval prolongation and mortality across rural and urban inpatient facilities.
20225 citationsauthor #8
812-P: Real-World Persistence, Adherence, Health Care Resource Utilization (HRU) , and Hypoglycemia in People with Type 2 Diabetes (T2D) Continuing the 2nd-Generation (2nd-Gen) Basal Insulin (BI) (Glargine 300 U/mL [Gla-300]) vs. Switching to a 1st-Generation (1s)
20220 citationsauthor #3
Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates.
202220 citationsauthor #3
Overriding Drug-Drug Interaction Alerts in Clinical Decision Support Systems: A Scoping Review
202220 citationsauthor #8
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis
20216 citationsauthor #9
Establishing a multidisciplinary initiative for interoperable electronic health record innovations at an academic medical center
202134 citationsauthor #39
Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States
202119 citationsauthor #2
Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade
202114 citationsauthor #8
Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder
202113 citationsauthor #4
ALL-190: Cost-Effectiveness of KTE-X19 for Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in the United States
20211 citationsauthor #7
Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis
20215 citationsauthor #5
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe.
202118 citationsauthor #9
Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries.
20216 citationsauthor #4
A Minimal Information Model for Potential Drug-Drug Interactions
202113 citationsauthor #17
Value of Active Warming Devices for Intraoperative Hypothermia Prevention—A Meta-Analysis and Cost-Benefit Analysis
202115 citationsauthor #6
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)
202141 citationsauthor #9
Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients
20212 citationsauthor #5
Designing and evaluating contextualized drug–drug interaction algorithms
202119 citationsauthor #9
Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose
202113 citationsauthor #7
Activity Measure for Post-Acute Care “6-Clicks” for the Prediction of Short-term Clinical Outcomes in Individuals Hospitalized With COVID-19: A Retrospective Cohort Study
202111 citationsauthor #6
Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder
20212 citationsauthor #4
Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder
202112 citationsauthor #6
Payer perceptions of the use of real-world evidence in oncology-based decision making
20219 citationsauthor #5
The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study
202113 citationsauthor #4
Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial
202130 citationsauthor #12
The Amortization of Funding Gene Therapies: Making the 'Intangibles' Tangible for Patients
20212 citationsauthor #11
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder
202113 citationsauthor #2
Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis
202039 citationsauthor #9
Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report.
202017 citationsauthor #1
HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications
20201 citationsauthor #2
Real-world evidence enhances decision making
20201 citationsauthor #1
DMD & BMD – CLINICAL
20200 citationsauthor #3
Health Outcomes Associated with Adherence to Antidepressant Use during Acute and Continuation Phases of Depression Treatment among Older Adults with Dementia and Major Depressive Disorder
20206 citationsauthor #7
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
202023 citationsauthor #10
Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial (Preprint)
20200 citationsauthor #12
Integrating the Practical Robust Implementation and Sustainability Model With Best Practices in Clinical Decision Support Design: Implementation Science Approach
202045 citationsauthor #9
Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
20205 citationsauthor #3
Evidence of Clinically Meaningful Drug–Drug Interaction With Concomitant Use of Colchicine and Clarithromycin
202024 citationsauthor #8
Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study
202035 citationsauthor #9
Dual-Trajectories of Opioid and Gabapentinoid Use and Risk of Subsequent Drug Overdose among Medicare Beneficiaries in the United States: A Retrospective Cohort Study.
202033 citationsauthor #6
Integrating the Practical Robust Implementation and Sustainability Model With Best Practices in Clinical Decision Support Design: Implementation Science Approach (Preprint)
20200 citationsauthor #9
Extent and Factors Associated with Adherence to Antidepressant Treatment During Acute and Continuation Phase Depression Treatment Among Older Adults with Dementia and Major Depressive Disorder
20204 citationsauthor #5
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
202076 citationsauthor #3
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
2020226 citationsauthor #20
Patient Treatment Preferences for Heart Failure Medications: A Mixed Methods Study
20208 citationsauthor #7
Safety of intraoperative hypothermia for patients: meta-analyses of randomized controlled trials and observational studies
202032 citationsauthor #5
Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
20201 citationsauthor #5
PGI27 GASTROINTESTINAL BLEEDING WITH CONCOMITANT EXPOSURE TO WARFARIN AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: A SYSTEMATIC REVIEW AND META-ANALYSIS
20200 citationsauthor #9
Clinician preferences for computerised clinical decision support for medications in primary care: a focus group study
201957 citationsauthor #11
PRO10 USE OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY TYPE 1: A UNITED STATES PAYER BUDGET IMPACT ANALYSIS
20192 citationsauthor #1
Lifetime Work Productivity Gains Among Patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) Treated with EDS‐FLU: 853
20192 citationsauthor #6
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients
201977 citationsauthor #1
PND23 HEALTHCARE EXPENDITURES ASSOCIATED WITH ADHERENCE TO ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER
20190 citationsauthor #3
Testing the face validity and inter-rater agreement of a simple approach to drug-drug interaction evidence assessment
20195 citationsauthor #3
PND92 EXTENT AND FACTORS ASSOCIATED WITH ADHERENCE TO APPROPRIATE ANTIDEPRESSANT TREATMENT DURING ACUTE AND CONTINUATION PHASE DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER
20190 citationsauthor #5
Identifying Common Methods Used by Drug Interaction Experts for Finding Evidence About Potential Drug-Drug Interactions: Web-Based Survey
201917 citationsauthor #5
Implementation of Clinical Decision Support Services to Detect Potential Drug-Drug Interaction Using Clinical Quality Language
201912 citationsauthor #4
PH2 DUAL-TRAJECTORIES OF OPIOID AND GABAPENTINOID USE AND RISK OF SUBSEQUENT DRUG OVERDOSE AMONG UNITED STATES MEDICARE BENEFICIARIES
20191 citationsauthor #6
Biosimilars : Considerations for Payers Table 1 Biosimilars
20190 citationsauthor #2
PBI1 THE VALUE OF ONASEMNOGENE ABEPARVOVEC (AVXS-101) AS A COST-EFFECTIVE GENE REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 IN IMPROVING SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND MOTOR FUNCTION
20191 citationsauthor #1
Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015.
20194 citationsauthor #4
PDG73 TRENDS, PATIENT AND PRESCRIBER CHARACTERISTICS AND OFF-LABEL USE OF GABAPENTINOIDS AMONG UNITE STATES AMBULATORY CARE VISITS FROM 2003-2015
20190 citationsauthor #5
PMU75 EMERGING TRENDS IN US HTA: A SYSTEMATIC REVIEW OF ICER VALUE ASSESSMENTS TO IDENTIFY FACTORS ASSOCIATED WITH RECOMMENDATIONS
20190 citationsauthor #2
PND3 HEALTH OUTCOMES ASSOCIATED WITH ADHERENCE TO HEALTHCARE EFFECTIVENESS DATA AND INFORMATION SET (HEDIS) ANTIDEPRESSANT MEDICATION MANAGEMENT MEASURES DURING ACUTE AND CONTINUATION PHASES OF DEPRESSION TREATMENT AMONG OLDER ADULTS WITH DEMENTIA AND MAJOR DEPRESSIVE DISORDER
20190 citationsauthor #5

TIMELINE

1993 11 citations

1997 909 citations

1998 109 citations

1999 93 citations

2000 723 citations

2001 760 citations

2002 15 citations

2003 128 citations

2004 758 citations

2005 272 citations

2006 1,081 citations

2007 472 citations

2008 223 citations

2009 476 citations

2010 64 citations

2011 474 citations

2012 371 citations

2013 247 citations

2014 99 citations

2015 485 citations

2016 495 citations

2017 82 citations

2018 246 citations

2019 373 citations

2020 576 citations

2021 311 citations

2022 227 citations

2023 102 citations

Unknown 0 citations

D. Malone

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT